Skip to main content
European Commission logo print header

The Development of Immunotherapeutic Strategies to Treat Haematological and Neoplastic diseases on the Basis of Optimised Allogeneic Stem Cell Transplantation

Objective

Haematological disease, either malignant or otherwise, carries a significant burden of morbidity and mortality. Recent advances in mapping and sequencing of the human genome make possible an approach to the treatment of these diseases which exploits the genetic differences between individuals to produce targets through which the immune system can eliminate the diseased cells. In practice this process of immunotherapy involves an allogeneic haematopoietic stem cell transplant, with subsequent delivery of specific immune effector cells expanded from the donor. The AlloStem project brings together clinical and research groups from across the EU who individually is amongst the world leaders in the field of immunotherapy to coordinate and complement their efforts into a unified and directed program. We will develop new protocols for the treatment of patients with haematological disease and for the effective delivery of immunogenomics-based therapies. The end results of the project will be both an improvement in the health care for EU citizens and the development of new genome-based pharmaceuticals that can be exploited worldwide.

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Coordinator

THE ANTHONY NOLAN TRUST
Address
The royal free hospital, pond street, hampstead
London
United Kingdom

See on map

Links
EU contribution
€ 0,00

Participants (28)